As of July 18, 2026, Enlivex Ltd. reported a net asset value (NAV) per ordinary share of $66.16 and held 79,550,593,122 RAIN tokens with a total treasury valuation of approximately $1.1 billion. The company's treasury strategy is built around the Rain protocol on the Arbitrum network. Enlivex is a longevity company that develops clinical-stage immunotherapy for inflammatory conditions associated with aging.
